Complications

People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care.

Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.

Healthcare professionals should follow our general guidelines for people delivering care:

Read this guideline alongside the NHS Type 2 diabetes Path to Remission Programme.

1.37 Periodontitis

1.37.1

Advise adults with type 2 diabetes at their annual review that:

  • they are at higher risk of periodontitis

  • if they get periodontitis, managing it can improve their blood glucose control and can reduce their risk of hyperglycaemia. [2022]

1.37.4

For adults with type 2 diabetes who have been diagnosed with periodontitis by an oral healthcare or dental team, offer dental appointments to manage and treat their periodontitis (at a frequency based on their oral health needs). [2022]

For a short explanation of why the committee made the 2022 recommendations, see the rationale and impact section on periodontitis.

Full details of the evidence and the committee's discussion are in evidence review D: periodontitis.

1.38 Gastroparesis

1.38.1

Think about a diagnosis of gastroparesis in adults with type 2 diabetes who have erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses. [2009, amended 2015]

1.38.2

For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that:

  • there is no strong evidence that any available antiemetic therapy is effective

  • some people have had benefit with domperidone, erythromycin or metoclopramide

  • the strongest evidence for effectiveness is for domperidone, but prescribers must take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. [2015]

    In February 2026, the use of erythromycin was off label. See NICE's information on prescribing medicines.

1.38.3

To treat vomiting caused by gastroparesis in adults with type 2 diabetes:

1.38.4

If gastroparesis is suspected, consider referring adults with type 2 diabetes to specialist services if:

  • the differential diagnosis is in doubt or

  • the person has persistent or severe vomiting. [2009]

1.39 Painful diabetic neuropathy

1.40 Autonomic neuropathy

1.40.1

Think about the possibility of contributory sympathetic nervous system damage in adults with type 2 diabetes who lose the warning signs of hypoglycaemia. [2009, amended 2015]

1.40.2

Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night. [2009, amended 2015]

1.40.4

For adults with type 2 diabetes who have unexplained bladder‑emptying problems, investigate the possibility of autonomic neuropathy affecting the bladder. [2009]

1.40.5

In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea). [2009]

1.41 Diabetic foot problems

1.42 Erectile dysfunction

1.42.1

As part of the type 2 diabetes annual review, offer to discuss erectile dysfunction (if relevant). [2015]

1.42.2

Assess, educate and support people with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. [2015]

1.42.3

Consider a phosphodiesterase‑5 inhibitor to treat problematic erectile dysfunction in people with type 2 diabetes. Initially choose the medicine with the lowest acquisition cost and take into account any contraindications. [2015]

1.42.4

After discussion, refer people with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase‑5 inhibitor, as appropriate) has been unsuccessful. [2015]

1.43 Eye disease

1.43.1

When adults are diagnosed with type 2 diabetes, refer them immediately to the local eye screening service. [2009, amended 2020]

1.43.2

Encourage adults to attend eye screening, and explain that it will help them to keep their eyes healthy and help to prevent problems with their vision. Explain that the screening service is effective at identifying problems so that they can be treated early. [2009]

1.43.3

Arrange emergency review by an ophthalmologist for:

  • sudden loss of vision

  • rubeosis iridis

  • pre-retinal or vitreous haemorrhage

  • retinal detachment. [2009]

For guidance on managing and monitoring diabetic retinopathy in people under the care of hospital eye services, see NICE's guideline on diabetic retinopathy.

1.44 Diagnosing and managing hypertension

The recommendations on diagnosing and managing hypertension have been removed. For recommendations on hypertension in people with type 2 diabetes, see NICE's guideline on hypertension in adults. Diagnosis, treatment and monitoring of hypertension is broadly the same for people with type 2 diabetes as for other people. When a different approach is needed for people with type 2 diabetes, this is specified in the hypertension guideline.

1.45 Antiplatelet therapy

1.45.1

Do not offer antiplatelet therapy (aspirin or clopidogrel) to adults with type 2 diabetes without cardiovascular disease. [2015]